Sermorelin
Sermorelin is a synthetic GHRH(1-29) analog that acts as a growth-hormone-releasing-hormone receptor agonist to stimulate pulsatile endogenous GH release; research protocols typically use 250 mcg subcutaneously, 5 days on/2 off, dosed nightly.
Sermorelin has been studied as a GHRH-receptor agonist for stimulating endogenous, pulsatile growth-hormone release, and historically for diagnostic assessment of pituitary GH secretory capacity, with research interest in age-related GH decline, sleep, recovery, and body composition.
Sermorelin is a synthetic 29-amino-acid peptide corresponding to the 1-29 N-terminal fragment of endogenous human growth hormone-releasing hormone (GHRH/GRF), the shortest fragment that retains full GHRH activity; it is supplied as an amidated acetate salt. Research has characterized it as a GHRH-receptor (GHRHR) agonist on anterior-pituitary somatotrophs, where binding stimulates the pituitary to synthesize and secrete its own growth hormone in discrete, physiologic pulses rather than supplying exogenous GH. Because the pituitary remains the rate-limiting step, this secretagogue pathway has been studied as preserving negative-feedback regulation and the natural pulsatile GH rhythm.
Sermorelin was previously FDA-approved (brand Geref) for assessing pituitary GH secretory capacity and was investigated in pediatric growth failure, but the manufacturer discontinued it in 2008; it is no longer marketed as an FDA-approved drug and is now encountered as a compounded or research compound.
In published research and historical labeling it has been administered by subcutaneous injection, with secretagogue regimens typically explored as nightly dosing on an empty stomach to align with the natural overnight GH pulse.
Owing to its very short plasma half-life, research describes a GH pulse within roughly 5-30 minutes of subcutaneous administration, while changes in GH-dependent markers such as IGF-1 or body composition are studied over weeks to months.
In secretagogue research it is commonly combined with a ghrelin-mimetic GH secretagogue such as ipamorelin to engage a complementary release pathway, and is sometimes discussed alongside CJC-1295 within the GHRH class.
Log every dose, count every vial, and verify your batches — free in the goodtides app.
This page is educational reference material about compounds studied in research settings. It is not medical advice, and nothing here is a recommendation to buy, possess, or use any compound. Research findings described are from published literature; individual compounds may not be approved for human use. Talk to a licensed clinician about anything that affects your health.